Contents

Editorial
823 Tenasin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage
M Van Mechelen, R Lories

Thinking the unthinkable
825 Rheumatism in 2049: the age of all data
J Mucke, P Sewerin, M Schneider

Review
828 Tissue physiology revolving around the clock: circadian rhythms as exemplified by the intervertebral disc
H Morris, C P Goncalves, M Dudek, J Hoyland, Q J Meng

Recommendation
840 EULAR recommendations for the reporting of ultrasonic studies in rheumatic and musculoskeletal diseases (RMDs)

Rheumatoid arthritis
848 Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

859 Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PeCARA study
H TW Smeele, E Roder, H M Wijnjies, L C Knabenberg-van Koppen, J AW Hazes, R JEM Dohlain

865 JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
P G Traves, B Murray, F Campigotto, R Gallien, A Meng, J A Di Paolo

876 Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4+ T cells through differential DNA methylation, explaining a substantial proportion of heritability
E Ha, S-Y Bang, J Lim, J H Yun, J-M Kim, J-B Baek, H-S Lee, B-J Kim, K Kim, S-C Bae

Inflammatory arthritis
884 Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis
I Gesel, M Popescu, V Schimpf, G Supp, T Deimel, M Durechova, M Huke, M Loiskandl, P Studenic, M Zauner, J S Smolen, D Aletaha, P Mandl

Spondyloarthritis
891 Tenasin-C-mediated suppression of extracellular matrix adhesion force promotes enthesal new bone formation through activation of Hippo signalling in ankylosing spondylitis
Z Li, S Chen, H Cai, X Li, D Chen, W Hao, J Wang, Z Li, Z Zheng, Z Zhong, H Liu

Pain
903 Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAMMOTH Study)

Systemic sclerosis
912 Autoantibodies targeting telomere-associated proteins in systemic sclerosis
B I Adler, F Bon, PJ Wohlers, C O Bingham, A A Shash, C Greider, L Casciola-Rosen, A Rosen

Impact Factor: 16.102
Epidemiology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry


Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts


Letters

SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists

R Priori, G Pellegrino, S Giasfrancesco, C Alessandri, F Cecarelli, M Di Franco, V Ricciari, R Serro, A Sili Szaydull, F R Spinelli, F Conti

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

D J Wallace, F Figueras, W A Wegener, D M Goldenberg

Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort: a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology

T Sacko, T Nagasawa, Y Ukata, Y Taniguchi, M Yanagita, S Nishi, M Nagata, Y Yamazuki, T Saito, H Nakechima, M Kawano

Bone loss in patients with SAPHO syndrome: a preliminary study

X Chen, M Wang, W Cui, Z Wang

Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study

J Iuzzo

Response to: ‘Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease’ by Lai et al

D Alpizar Rodriguez, T R Lesker, B Gilbert, T Stowig, A Finckh

Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease

S-W Lai, Y-H Kuo, K-F Liao

Response to: ‘Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease’ by Lai et al

L Fardet, I Petersen, I Nazareth

MS score in systemic juvenile idiopathic arthritis: suitable for routine use?

H Chi, Z Wang, C Yang, Y Su

Response to: ‘MS score in systemic juvenile idiopathic arthritis: suitable for routine use?’ by Chi et al

F Minova, A Ravelli

Correspondence to ‘Time to change the primary outcome of lupus trials

S Oon, M Huq, M Nikpour

Response to Correspondence to ‘Time to change the primary outcome of lupus trials’ by Oon et al

F A Houssiau
Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren’s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren’s syndrome?
G Coiffier, A Martel, J-D Albert, A Lescoat, A Bleuzen, A Perdriger, M De Bandt, F Maillot

Response to: ‘Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren’s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren’s syndrome?’ by Coiffier et al

Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis
C Campochiaro, G De Luca, M De Santis

Response to: ‘Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis’ by Campochiaro et al
L Spielmann, F Séverac, A Meyer

Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’
M Infantino, M Manfredi, N Bizzaro

Response to: ‘Comment on: standardisation of myositis-specific antibodies: where are we today?’ by Infantino et al
J Rönnelid, F Espinosa-Ortega, I E Lundberg

Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype
L Gupta, S Ahmed, B Singh, S Prakash, S Phadke, A Aggarwal

Response to: ‘Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype’ by Gupta et al
C Eijkelboom, N M Ter Haar, J Frenkel, M Gattorno

How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
I Parodis, M Nikpour

Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
E Raschi, I C Antonazzo, E Poluzzi, F De Ponti

Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab
F Muratore, C Salvatoni